Trial Profile
Efficacy and Safety of Aclidinium Bromide at Two Dose Levels vs Placebo When Administered to Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Aclidinium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms ATTAIN
- Sponsors Almirall S.A.
- 22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
- 05 Sep 2012 Effects of treatment on disease exacerbations presented at the 22nd Annual Congress of the European Respiratory Society.
- 22 Mar 2012 Full results were published in the European Respiratory Journal, according to a Almirall media release.